Leerink notes that the shortage of Novo Nordisk’s (NVO) semaglutide, marketed as Wegovy and Ozempic, has been resolved according to the FDA.

Leerink reiterates an Outperform rating and $675 price target on shares of UnitedHealth (UNH). The Wall Street Journal reported that the ...

Fintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a ...

Stock analysts at Leerink Partnrs upped their Q1 2025 earnings per share (EPS) estimates for Neurocrine Biosciences in a report issued on Monday, February 17th. Leerink Partnrs analyst M. Goodman now ...

Analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Lantheus in a research note issued on Tuesday, February 18th. Leerink Partnrs analyst R. Ruiz forecasts that the ...

Over the last decade, as the Institute for Clinical and Economic Review (ICER) has estimated the cost-effectiveness of newly ...

Leerink Partners analyst Thomas Smith adjusted the price target for 89bio Inc . (NASDAQ:ETNB) to $37 from $34, while reiterating an Outperform rating on the stock. Currently trading at $9.60, the ...

An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied ...

U.S. District Judge Angel Kelley for the District of Massachusetts allowed state law claims to move forward in a suit brought by an investment banker who claims Leerink Partners failed to pay minimum ...

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief ...

Upstart investment bank SVB Leerink is no longer keeping mum on its ambitions to push into the red hot technology, media, and telecommunications market. The dealmaking unit of SVB Financial Group ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at Leerink Partners believe that Merck’s Winrevair “should have ...